Concentrated Growth Factors in Maxillary Sinus Floor Augmentation: A Preliminary Clinical Comparative Evaluation

Aims: The primary aim of this clinical study was to examine the effect of concentrated growth factors matrix (CGFm) on implant survival rate in augmented sinuses; the secondary aim was to evaluate the effect of CGFm on sinus augmentation postoperative morbidity. Materials and Methods: Fifty patients were selected from a pool of participants requiring maxillary sinus augmentation. Of these, 25 patients (control‑group) received a corticocancellous xenograft. The other 25 patients (test group) received a mixture of 70% CGF matrix and 30% corticocancellous xenograft. Venous blood samples were drawn from each patient and immediately centrifuged. Four components were identified vertically from top to bottom: (1) An upper liquid phase constituted by serum; (2) a phase constituted by polymerized fibrin buffy coat; (3) a middle phase constituted by aggregated platelets with CGFs; and (4) a lower phase constituted by red blood cells. The middle (second and third) phases represented the CGFm and were mixed with the graft material. The survival rate was calculated and comparison was made between the 2 different groups using Kaplan–Meier analysis. Statistical significance was set at P < 0.05. Results: A 96.4% survival rate was described in the test group (with CGFm) and a 96.1% survival rate in the control group (without CGFm). No statistically significant differences were observed between the survival rates of the two groups after 1 year. Conclusions: The mixture of CGFm (70%) with xenograft (30%) is an alternative to xenograft material alone and is a predictable procedure resulting in less postoperative morbidity in sinus augmentation.